IDRI wins $11.9M for thermostable TB vax; Immunovaccine's DPX-Survivac gets green light for PhII trial;

> The Infectious Disease Research Institute (IDRI) has won a $11.9 million contract from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop a thermostable TB vaccine. Release

> Health Canada has cleared Immunovaccine to conduct a Phase II clinical trial of DPX-Survivac in recurrent lymphoma. Release

> NewLink Genetics ($NLNK) has appointed Thomas Monath as the chief scientific and chief operations officer of its infectious disease division. Release

> TapImmune has teamed up with the Vaccine & Gene Therapy Institute of Florida (VGTI) to its breast cancer and ovarian cancer vaccines into Phase II trials. Release

> SRA International has won an $18 million contract to support the Vaccine Adverse Event Reporting System (VAERS), cosponsored by the CDC and the FDA. More

> Houston biotech Bellicum Pharmaceuticals is angling to raise $115 million in an IPO, funds that would help it bankroll a Phase I/II study for BPX-201, its dendritic cancer vaccine. More

> In a Phase I/II trial of 38 HIV-positive patients, Theravectys' lentiviral vector-based therapeutic vaccine elicited an immune response and showed no safety concerns. Release

And Finally... U.S. senators have introduced a bipartisan resolution to support vaccine alliance GAVI. Report

Suggested Articles

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.